Consumer Staples [ 12/12 ] | Personal Care Products [ 64/75 ]
NASDAQ | Common Stock
United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally The company offers cosmetic ingredients, including LUBRAJEL, a line of water-based gel formulation for sensory enhancement, lubrication, and texture to personal care products; LUBRAJEL NATURAL for skin moisturizing; LUBRAJEL MARINE that develops natural products using naturally derived polymers; LUBRAJEL OlL NATURAL, which makes luxuriant textures without adding viscosity; LUBRAJEL TERRA, a multifunctional, moisturizing hydrogel products; LUBRASIL II SB, a formulation of LUBRAJEL; LUBRAJEL II XD; B-122, a powdered lubricant used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; and ORCHID COMPLEX, an oil-soluble base for extract of fresh orchids used in fragrance products, such as perfumes and toiletries.
Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL MGL, a medical lubricant with a lower viscosity medical lubricant; LUBRAJEL LC, LUBRAJEL BA, and LUBRAJEL FA, which are formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products.
The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial used in urology.
Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser.
The company also conducts research and product development of cosmetic ingredients.
United-Guardian, Inc. was founded in 1942 and is based in Hauppauge, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 4, 24 | 0.19 Increased by +34.57% | - |
| Aug 9, 24 | 0.21 Increased by +107.27% | - |
| May 10, 24 | 0.20 Increased by +22.36% | - |
| Mar 22, 24 | 0.16 Increased by +7.00% | - |
| Nov 6, 23 | 0.14 Increased by +86.17% | - |
| Aug 11, 23 | 0.10 Decreased by -28.29% | - |
| May 11, 23 | 0.16 Decreased by -17.70% | - |
| Mar 17, 23 | 0.15 Decreased by -37.50% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 3.06 M Increased by +0.08% | 865.48 K Increased by +38.09% | Increased by +28.28% Increased by +37.97% |
| Jun 30, 24 | 3.39 M Increased by +27.92% | 956.23 K Increased by +107.38% | Increased by +28.21% Increased by +62.12% |
| Mar 31, 24 | 3.25 M Increased by +26.64% | 925.44 K Increased by +22.40% | Increased by +28.43% Decreased by -3.34% |
| Dec 31, 23 | 2.61 M Decreased by -5.64% | 737.44 K Increased by +8.57% | Increased by +28.29% Increased by +15.07% |
| Sep 30, 23 | 3.06 M Increased by +26.50% | 626.76 K Increased by +81.40% | Increased by +20.50% Increased by +43.40% |
| Jun 30, 23 | 2.65 M Decreased by -26.91% | 461.09 K Decreased by -27.19% | Increased by +17.40% Decreased by -0.39% |
| Mar 31, 23 | 2.57 M Decreased by -33.96% | 756.08 K Decreased by -17.05% | Increased by +29.42% Increased by +25.62% |
| Dec 31, 22 | 2.76 M Decreased by -24.53% | 679.21 K Decreased by -39.16% | Increased by +24.58% Decreased by -19.38% |